Composite probiotic preparation for relieving hyperuricemia and application thereof

By combining the strains of Bifidobacterium animalis subsp.lactis BLa80, Lactobacillus rhamnosus LRa05 and Bifidobacterium breve BBr60, a complex probiotic preparation for relieving hyperuricemia was developed, addressing the side effects and efficacy of existing treatments. First, the problem of achieving safe and efficient uric acid metabolism regulation and excretion effect.

CN118948902APending Publication Date: 2024-11-15JIANGSU WECARE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 5 Cited by

Patent Information

Application Number
CN202411232543.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing treatment methods for hyperuricemia have side effects and adverse reactions, and some patients have different efficacy against traditional drugs. The quality of probiotic products on the market is uneven, and there is a lack of effective probiotic-based treatment plans.

Method used

Developed a complex probiotic preparation including the shortest strain of Bifidobacterium animalis subsp.lactis BLa80 strain of CGMCC No. 15410, Lactobacillus rhamnosus LRa05 strain of CGMCC No. 1.12734 and CGMCC No. 12915 Bifidobacterium breve BBr60 strain, through a brand new probiotic complex method and strategy, works synergistically to alleviate hyperuricemia, reduce serum uric acid levels and xanthine oxidase activity.

Benefits of technology

This compound probiotic preparation significantly alleviates the increase in uric acid caused by hyperuricemia, reduces serum uric acid nitrogen level, improves uric acid excretion efficiency, and provides a safe and effective Treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948902A_ABST
    Figure CN118948902A_ABST
Patent Text Reader

Abstract

The invention relates to a compound probiotic preparation capable of relieving hyperuricemia and application of the compound probiotic preparation. The compound probiotic preparation capable of relieving the hyperuricemia comprises a Bifidobacterium animalis subsp. Lactis BLa80 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.15410, a Lactobacillus rhamnosus LRa05 strain with the preservation number of CGMCC No.1.12734, and a Bifidobacterium breve BBr60 strain with the preservation number of CGMCC No.12915. The compound probiotic preparation capable of relieving the hyperuricemia and the application of the compound probiotic preparation capable of relieving the hyperuricemia have the advantages that the compound probiotic preparation capable of relieving the hyperuricemia can be used for relieving the hyperuricemia; the three strains can be matched and promoted with one another, and have a synergistic effect on the aspect of relieving hyperuricemia, specifically, the phenomenon of uric acid increase caused by hyperuricemia is relieved, and the xanthine oxidase activity and the serum uric acid nitrogen level are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to a composite probiotic preparation for relieving hyperuricemia and an application thereof. Background Art

[0002] Hyperuricemia, as the main risk factor for gout, is closely related to the occurrence of various diseases such as hypertension, diabetes, cardiovascular disease and kidney disease, and has become one of the public health issues that endanger human life safety. Uric acid is the final product of purine metabolism and is mainly excreted through the kidneys and intestines. At present, traditional treatments for hyperuricemia mainly include drug therapy, such as uric acid synthesis inhibitors and uric acid excretion promoters. However, these drugs may have side effects and adverse reactions, such as gastrointestinal discomfort, rash, liver and kidney damage, etc., and some patients have different responses to their efficacy.

[0003] In recent years, with the deepening of intestinal microecological research, scientists have found that probiotics play an important role in regulating human health and promoting uric acid metabolism, providing new ideas for the treatment of hyperuricemia. As a type of active microorganisms that are beneficial to the human body, probiotics play an important role in maintaining the balance of intestinal flora, promoting nutrient absorption, and enhancing immunity. In recent years, many studies have shown that probiotics can affect uric acid metabolism through various mechanisms. When probiotics grow and reproduce in the intestine, they absorb purine substances for the synthesis of their own genetic genes, and degrade purine substances in the intestine by producing purine nucleosidases to reduce their further conversion into uric acid. Probiotics can enrich the intestinal flora, inhibit the growth of harmful bacteria, and restore the intestinal barrier function, thereby improving the intestinal environment for uric acid metabolism. Probiotics can promote the excretion of uric acid and reduce serum uric acid levels by affecting the expression of urate transporters.

[0004] Although probiotics have shown great potential in alleviating hyperuricemia, there are many types of probiotic products on the market with varying quality. In view of this, it is of great significance to develop more effective probiotic-based treatment options that can not only effectively lower uric acid levels but also reduce the need to rely on traditional drug treatments. Summary of the invention

[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide a composite probiotic preparation for alleviating hyperuricemia and its application, and specifically to a composite probiotic preparation for alleviating hyperuricemia and its application in the preparation of a medicament for preventing, improving or treating hyperuricemia.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a composite probiotic preparation for relieving hyperuricemia, wherein the strains in the composite probiotic preparation for relieving hyperuricemia include Bifidobacterium animalis subsp. lactis BLa80 strain with a preservation number of CGMCC No.15410, Lactobacillus rhamnosus LRa05 strain with a preservation number of CGMCC No.1.12734, and Bifidobacterium breve BBr60 strain with a preservation number of CGMCC No.12915.

[0008] The present invention develops a new probiotic compounding method and a new strategy for alleviating hyperuricemia, namely, Bifidobacterium animalis subsp.lactis BLa80 strain, Lactobacillus rhamnosus LRa05 strain and Bifidobacterium breve BBr60 strain are compounded for use, and it is found that the three can cooperate with each other, promote each other, and synergize in the effect of alleviating hyperuricemia, which is specifically manifested in: alleviating the phenomenon of uric acid elevation caused by hyperuricemia, reducing xanthine oxidase activity and serum uric acid nitrogen level. In addition, all three bacteria are probiotics, the product is highly safe, and it is not easy to produce resistance.

[0009] Preferably, the content of live bacteria in the composite probiotic preparation is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL, for example 1×10 8 CFU / g (CFU / mL), 1×10 9 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 5×10 10 CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 3×10 11 CFU / g (CFU / mL), 5×10 11 CFU / g (CFU / mL), 1×10 12 CFU / g (CFU / mL), 1×10 13 CFU / g (CFU / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0010] Preferably, the ratio of the number of viable bacteria of the BLa80 strain, LRa05 strain and BBr60 strain is (1-10):(1-10):(1-10), wherein the specific point values ​​in (1-10) can be independently selected as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc., and will not be repeated here.

[0011] Preferably, the dosage form of the composite probiotic preparation includes solution, lyophilized powder, capsule, tablet or granule. The dosage form of the probiotic preparation involved in the present invention is not limited, including the most commonly used solution, lyophilized powder, or further prepared capsule, tablet or granule.

[0012] Preferably, the dosage form of the composite probiotic preparation is a freeze-dried powder, which is prepared by the following method:

[0013] The BLa80 strain, LRa05 strain and BBr60 strain are inoculated into a culture medium respectively, activated and fermented in sequence to obtain a fermentation broth; the fermentation broth is centrifuged to obtain a bacterial sludge; the bacterial sludge is mixed with a protective agent and resuspended to obtain a resuspension; the resuspension is freeze-dried to obtain BLa80 bacterial powder, LRa05 bacterial powder and BBr60 bacterial powder; BLa80 bacterial powder, LRa05 bacterial powder and BBr60 bacterial powder are mixed according to the ratio of live bacteria count to obtain the composite probiotic preparation.

[0014] Preferably, the protective agent is selected from any one or a combination of at least two of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.

[0015] Preferably, the fermentation culture temperature is 35-40°C, for example, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, etc.; the time is 12-30h, for example, 12h, 15h, 16h, 18h, 20h, 24h, 28h, 30h, etc.; other specific point values ​​within the above numerical range can be selected, and they will not be described one by one here.

[0016] Preferably, the inoculation amount is 1-5%, for example 1%, 2%, 3%, 4%, 5%, etc. Other specific point values ​​within the numerical range can be selected and will not be described one by one here.

[0017] Preferably, the culture medium is MRS medium.

[0018] In a second aspect, the present invention provides use of the composite probiotic preparation described in the first aspect in the preparation of a medicament for preventing, improving or treating hyperuricemia.

[0019] Preferably, the medicine further contains excipients.

[0020] Preferably, the auxiliary materials include any one or a combination of at least two of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention creatively develops a new probiotic compounding method and a new strategy for alleviating hyperuricemia, that is, compounding Bifidobacterium animalis lactis subsp. BLa80 strain, Lactobacillus rhamnosus LRa05 strain and Bifidobacterium breve BBr60 strain, and finds that the three can cooperate with each other, promote each other, and synergize in the effect of alleviating hyperuricemia, which is specifically manifested in: alleviating the increase of uric acid caused by hyperuricemia, and reducing xanthine oxidase activity and serum uric acid nitrogen levels.

[0023] The BLa80 strain involved in the present invention is classified and named as Bifidobacterium animalis subsp. lactis, and the preservation unit is the General Microbiology Center of China Microbiological Culture Collection Administration, the preservation time is March 5, 2018, the preservation number is CGMCC No.15410, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0024] The LRa05 strain involved in the present invention is classified and named Lactobacillus rhamnosus, and the preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration. The preservation time is July 20, 2020, the preservation number is CGMCC No.1.12734, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0025] The BBr60 strain involved in the present invention is classified and named as Bifidobacterium breve, and the depository is the General Microbiological Center of China Microbiological Culture Collection Administration, the deposit time is August 29, 2016, the deposit number is CGMCC No.12915, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is the statistical result of serum uric acid content of rats in each group on the 7th day;

[0027] Figure 2 is the statistical result graph of serum uric acid content of rats in each group on the 28th day;

[0028] Figure 3This is the statistical result of fecal uric acid content of rats in each group on the 28th day;

[0029] Figure 4 This is the statistical result of fecal uric acid excretion of rats in each group on the 28th day;

[0030] Figure 5 is the statistical result graph of serum xanthine oxidase activity of rats in each group on the 28th day;

[0031] Figure 6 This is a statistical graph of serum urea nitrogen activity in each group of rats on the 28th day. DETAILED DESCRIPTION

[0032] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0033] The culture medium formula involved in the following examples is as follows:

[0034] MRS medium: peptone 10g / L, beef extract 10g / L, glucose 20g / L, sodium acetate 2g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2PO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4 0.05g / L, Tween 801mL / L, cysteine ​​hydrochloride 0.5g / L.

[0035] The BLa80 strain involved in the following examples is classified and named as Bifidobacterium animalis subsp. lactis, the preservation time is March 5, 2018, and the preservation number is CGMCC No.15410.

[0036] The LRa05 strain involved in the following examples is classified and named Lactobacillus rhamnosus, with a preservation date of July 20, 2020 and a preservation number of CGMCC No.1.12734.

[0037] The BBr60 strain involved in the following examples is classified and named as Bifidobacterium breve, and the deposit date is August 29, 2016, and the deposit number is CGMCC No.12915.

[0038] The preparation method of the probiotic powder involved below: seed liquid of BLa80 strain, LRa05 strain and BBr60 strain are inoculated into MRS medium at an inoculation amount of 3% of the total mass of the medium, and cultured at 37°C for 18 hours to obtain culture liquid; the culture liquid is centrifuged to obtain bacterial cells; the bacterial cells are resuspended with a freeze-drying protective agent (a trehalose aqueous solution with a concentration of 100g / L), and the mass ratio of the freeze-drying protective agent to the bacterial cells is 2:1 to obtain a resuspension; the resuspension is freeze-dried by a vacuum freezing method to obtain freeze-dried powders of the three bacteria. BLa80 freeze-dried powder, LRa05 freeze-dried powder and BBr60 freeze-dried powder are mixed in two or three ways according to the ratio of the number of live bacteria.

[0039] The experimental results were statistically analyzed using ggplot2 in R language. Compared with the control group, ### represents p<0.001, ## represents p<0.01, and # represents p<0.05; compared with the model group, *** represents p<0.001, ** represents p<0.01, and * represents p<0.05.

[0040] Example

[0041] This example explores the ability of the composite probiotic preparation to improve symptoms in a hyperuricemia rat model:

[0042] (1) Experimental animals: 80 healthy SPF male 7-week-old SD rats, which were housed in a controlled environment with room temperature maintained at 22-26°C, humidity at 50-60%, and a 12-h light / dark cycle. They were allowed to eat and drink freely.

[0043] (2) Animal grouping: After one week of adaptive feeding, the rats were randomly divided into 10 groups, with 8 rats in each group: control group (CTL), hyperuricemia model group (MC group), allopurinol group (PG group, positive control), S1 group (combined intervention with BLa80 freeze-dried powder and LRa05 freeze-dried powder, with a live bacteria count ratio of 1:1), S2 group (combined intervention with BLa80 freeze-dried powder and BBr60 freeze-dried powder, with a live bacteria count ratio of 1:1), S3 group (combined intervention with LRa05 freeze-dried powder and BBr60 freeze-dried powder, with a live bacteria count ratio of 1:1), S4 group (combined intervention with BLa80 freeze-dried powder, LRa05 freeze-dried powder and BBr60 freeze-dried powder, with a live bacteria count ratio of 1:1), The following groups were selected: (1) group S5 (combined intervention with BLa80 lyophilized powder, LRa05 lyophilized powder and BBr60 lyophilized powder, with the ratio of viable bacteria being 1:1:1); (2) group S6 (combined intervention with BLa80 lyophilized powder, LRa05 lyophilized powder and BBr60 lyophilized powder, with the ratio of viable bacteria being 1:1:10); and (3) group S7 (commercially available animal Bifidobacterium lactis subsp. lactis ATCC700541 lyophilized powder, commercially available Lactobacillus rhamnosus ATCC53103 lyophilized powder and commercially available Bifidobacterium segmentum ATCC15700 lyophilized powder, with the ratio of viable bacteria being 1:1:1).

[0044] (3) Animal modeling and intervention methods:

[0045] Except for the control group, the other groups were fed with a diet containing 2.5% uric acid and given 750 mg / kg body weight of potassium oxonate by gavage every day. On the 7th day of the experiment, blood was collected from the orbital vein after ether anesthesia to detect the uric acid level in the blood to confirm whether the model was successfully established. Subsequently, starting from the 8th day, the probiotic intervention group was given 2.5×10 9 The mice were given lyophilized powder solution of probiotics (solvent: normal saline) at a dose of 30 mg / kg body weight in the allopurinol group, while the control group and the model group were given an equal volume of normal saline.

[0046] (4) Sample collection:

[0047] The experiment lasted until the 28th day, when the rats were anesthetized with ether again, blood was drawn to obtain serum samples, and fecal samples were collected. The uric acid content in serum and feces was detected by an automatic biochemical analyzer, and the urea nitrogen content in serum was detected; the xanthine oxidase activity in serum was determined by a xanthine oxidase activity detection kit. The fecal uric acid excretion was also calculated, and the fecal uric acid excretion = fecal uric acid concentration × fecal weight.

[0048] (5)Indicator analysis:

[0049] (5.1) Changes in serum uric acid levels in rats on day 7:

[0050] like Figure 1 As shown, after 7 consecutive days of oral administration of potassium oxonate combined with a high-uric acid diet, the serum uric acid levels of rats in other groups increased significantly compared with the control group, confirming the successful establishment of the hyperuricemia model.

[0051] (5.2) Changes in serum uric acid levels in rats on day 28:

[0052] After 21 days of continuous intervention, Figure 2 As shown, compared with the hyperuric acid model group, the serum uric acid levels of rats in all probiotic intervention groups and allopurinol intervention groups decreased to varying degrees, among which the combined intervention effect of BLa80 freeze-dried powder, LRa05 freeze-dried powder and BBr60 freeze-dried powder was better than that of other compound formulas.

[0053] (5.3) Changes in fecal uric acid content in rats on day 28:

[0054] After 21 days of continuous intervention, Figure 3 As shown, compared with the hyperuric acid model group, the uric acid content in the feces of rats in all probiotic intervention groups and allopurinol intervention groups was reduced to varying degrees, among which the effect of combined intervention of BLa80 freeze-dried powder, LRa05 freeze-dried powder and BBr60 freeze-dried powder was more significant.

[0055] (5.4) Changes in fecal uric acid excretion in rats on day 28:

[0056] After 21 days of intervention, Figure 4 As shown, compared with the hyperuric acid model group, the fecal uric acid excretion of rats in all probiotic intervention groups and allopurinol intervention groups was reduced to varying degrees, among which the combined intervention of BLa80 freeze-dried powder, LRa05 freeze-dried powder and BBr60 freeze-dried powder was more effective in reducing uric acid excretion.

[0057] By measuring fecal uric acid content and excretion, the immediate and long-term effects of the intervention on uric acid metabolism were comprehensively evaluated, thereby more accurately understanding its regulatory effects on the uric acid excretion pathway in rats.

[0058] (5.5) Changes in serum xanthine oxidase activity in rats on day 28:

[0059] like Figure 5 The results of serum xanthine oxidase activity test showed that hyperuricemia caused the enzyme activity in rat serum to increase significantly compared with the control group. On the 28th day, the xanthine oxidase activity in each probiotic intervention group and the allopurinol intervention group was significantly lower than that in the hyperuricemia model group, indicating that the probiotic preparation involved in the present invention can inhibit the activity of xanthine oxidase in the serum of hyperuricemia rats, and the effect of the three-strain compound formula is better than other compound formulas.

[0060] (5.6) Changes in serum urea nitrogen activity in rats on day 28:

[0061] like Figure 6 The results showed that on the 28th day, the serum urea nitrogen level of rats in the hyperuricemia model group was significantly higher than that in the control group, indicating that hyperuricemia can cause inflammatory response and renal damage in rats. The urea nitrogen content of each probiotic intervention group was lower than that of the model group, reflecting that the probiotic preparation involved in the present invention helps to alleviate renal damage in rats with hyperuricemia, and the three-strain compound formula is more effective in reducing urea nitrogen.

[0062] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0063] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0064] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A composite probiotic preparation for relieving hyperuricemia, It is characterized in that The strains in the composite probiotic preparation for relieving hyperuricemia include Bifidobacterium animalis subsp. lactis BLa80 strain with a preservation number of CGMCC No.15410, Lactobacillus rhamnosus LRa05 strain with a preservation number of CGMCC No.1.12734, and Bifidobacterium breve BBr60 strain with a preservation number of CGMCC No.12915.

2. The composite probiotic preparation according to claim 1, It is characterized in that The content of live bacteria in the composite probiotic preparation is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

3. The composite probiotic preparation according to claim 1, It is characterized in that The ratio of the number of viable bacteria among the BLa80 strain, the LRa05 strain and the BBr60 strain is (1-10):(1-10):(1-10).

4. The composite probiotic preparation according to claim 1, It is characterized in that The dosage form of the composite probiotic preparation includes solution, lyophilized powder, capsule, tablet or granule.

5. The composite probiotic preparation according to claim 4, It is characterized in that The dosage form of the composite probiotic preparation is a freeze-dried powder, which is prepared by the following method: The BLa80 strain, LRa05 strain and BBr60 strain are inoculated into a culture medium respectively, activated and fermented in sequence to obtain a fermentation broth; the fermentation broth is centrifuged to obtain a bacterial sludge; the bacterial sludge is mixed with a protective agent and resuspended to obtain a resuspension; the resuspension is freeze-dried to obtain BLa80 bacterial powder, LRa05 bacterial powder and BBr60 bacterial powder; BLa80 bacterial powder, LRa05 bacterial powder and BBr60 bacterial powder are mixed according to the ratio of live bacteria count to obtain the composite probiotic preparation.

6. The composite probiotic preparation according to claim 5, It is characterized in that The protective agent is selected from any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

7. The composite probiotic preparation according to claim 5, It is characterized in that The fermentation culture temperature is 35-40°C and the time is 12-30h; Preferably, the inoculation amount of the inoculation is 1-5%; Preferably, the culture medium is MRS medium.

8. Use of the composite probiotic preparation according to any one of claims 1 to 7 in the preparation of a medicament for preventing, improving or treating hyperuricemia.

9. The use according to claim 8, It is characterized in that The medicine also contains auxiliary materials.

10. The use according to claim 9, It is characterized in that The auxiliary materials include any one of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers, or a combination of at least two of them.

Citation Information

Cited By

  • Compound probiotics for preventing, relieving or treating hyperlipidemia and application thereof

    CN119709555A

  • Application of bacillus coagulans BC99 in preparation of probiotic preparation for assisting in reducing uric acid level

    CN119770526A

  • Microbial agent for relieving hyperuricemia and application thereof

    CN120210077A

  • Probiotic symbiotic biological membrane and application thereof in preparation of products for prevention or adjuvant treatment of alcoholic liver diseases

    CN122124115A

  • Composite probiotic formulation for alleviating hyperuricemia and use thereof

    WO2026051421A1